Shandong Boan Biotechnology Co., Ltd. (FRA:UJ9)
Germany
· Delayed Price · Currency is EUR 0.980
+0.025 (2.62%)
At close: Dec 5, 2025
FRA:UJ9 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 756.78 | 726.32 | 618.13 | 515.96 | 158.7 | - |
| Revenue Growth (YoY) | 5.13% | 17.50% | 19.80% | 225.11% | - | - |
| Cost of Revenue | 214.18 | 183.66 | 209.16 | 161.73 | 52.19 | - |
| Gross Profit | 542.61 | 542.65 | 408.97 | 354.23 | 106.51 | - |
| Selling, General & Admin | 356.73 | 332.3 | 308.22 | 296.42 | 96.21 | 4.46 |
| Research & Development | 122.05 | 149.27 | 230.68 | 400.34 | 231.57 | 236.32 |
| Operating Expenses | 478.77 | 481.58 | 538.9 | 696.76 | 327.78 | 240.78 |
| Operating Income | 63.84 | 61.08 | -129.93 | -342.53 | -221.27 | -240.78 |
| Interest Expense | -39.59 | -32.65 | -14.09 | -13.41 | -11.6 | -11.82 |
| Interest & Investment Income | 0.21 | 0.41 | 1.16 | 5.57 | 9.1 | 1.2 |
| Currency Exchange Gain (Loss) | - | - | - | 2.38 | - | - |
| Other Non Operating Income (Expenses) | 7.57 | 44.36 | 23.49 | 16.24 | -1.65 | 10.88 |
| EBT Excluding Unusual Items | 32.03 | 73.19 | -119.38 | -331.75 | -225.42 | -240.53 |
| Gain (Loss) on Sale of Assets | - | - | - | - | - | -0.01 |
| Pretax Income | 32.03 | 73.19 | -119.38 | -331.75 | -225.42 | -240.54 |
| Net Income | 32.03 | 73.19 | -119.38 | -331.75 | -225.42 | -240.54 |
| Net Income to Common | 32.03 | 73.19 | -119.38 | -331.75 | -225.42 | -240.54 |
| Shares Outstanding (Basic) | 568 | 536 | 509 | 499 | 479 | 39 |
| Shares Outstanding (Diluted) | 568 | 536 | 509 | 499 | 479 | 39 |
| Shares Change (YoY) | 11.62% | 5.23% | 2.14% | 4.19% | 1119.88% | - |
| EPS (Basic) | 0.06 | 0.14 | -0.23 | -0.67 | -0.47 | -6.13 |
| EPS (Diluted) | 0.06 | 0.14 | -0.23 | -0.67 | -0.47 | -6.13 |
| Free Cash Flow | 43.98 | -184.53 | -85.89 | -283.13 | -354.01 | -531.77 |
| Free Cash Flow Per Share | 0.08 | -0.34 | -0.17 | -0.57 | -0.74 | -13.55 |
| Gross Margin | 71.70% | 74.71% | 66.16% | 68.66% | 67.12% | - |
| Operating Margin | 8.43% | 8.41% | -21.02% | -66.39% | -139.42% | - |
| Profit Margin | 4.23% | 10.08% | -19.31% | -64.30% | -142.04% | - |
| Free Cash Flow Margin | 5.81% | -25.41% | -13.89% | -54.87% | -223.06% | - |
| EBITDA | 119.42 | 104.28 | -76.34 | -292.56 | -188.72 | -227.68 |
| EBITDA Margin | 15.78% | 14.36% | -12.35% | -56.70% | -118.91% | - |
| D&A For EBITDA | 55.58 | 43.2 | 53.59 | 49.97 | 32.55 | 13.1 |
| EBIT | 63.84 | 61.08 | -129.93 | -342.53 | -221.27 | -240.78 |
| EBIT Margin | 8.43% | 8.41% | -21.02% | -66.39% | -139.42% | - |
Source: S&P Capital IQ. Standard template. Financial Sources.